Last updated: January 30, 2026
Executive Summary
Guselkumab (trade name Tremfya) is a monoclonal antibody developed by Janssen Pharmaceuticals targeting interleukin-23 (IL-23), used primarily for psoriasis and other immune-mediated conditions. With a broad clinical development portfolio and FDA approval since 2017, guselkumab continues to expand its indications, clinical trial presence, and market penetration. This report synthesizes recent clinical trials, evaluates market dynamics, and projects future growth over the next five years.
Current Clinical Trial Landscape for Guselkumab
Overview of Active and Recruiting Trials
As of Q1 2023, there are 35 active or recruiting clinical trials globally, focusing on psoriasis, psoriatic arthritis, Crohn’s disease, atopic dermatitis, and other immune conditions.
| Trial Status |
Number of Trials |
Focus Areas |
Geographies |
| Recruiting |
15 |
Psoriasis, psoriatic arthritis, Crohn’s |
North America, Europe, APAC |
| Ongoing |
10 |
Atopic dermatitis, ulcerative colitis |
US, EU, Japan |
| Completed |
10 |
Phase 3 efficacy and safety assessments |
Worldwide |
Note: Data sourced from ClinicalTrials.gov (search term: Guselkumab, 2023).
Recent Phase 3 Trials Insights
- VOYAGE 1 & 2 (2018): Demonstrated superiority over placebo and adalimumab in psoriasis severity metrics (PASI 90/100).
- NAVIGATE (2022): Evaluated guselkumab in biologic-experienced psoriatic arthritis patients, confirming efficacy and safety.
- VOYAGE 3 (2023): Focused on quality of life measures and long-term safety over 4 years.
Key Efficacy and Safety Data
| Study |
Patient Population |
Primary Endpoint |
Efficacy (PASI 90 at Week 16) |
Adverse Events |
| VOYAGE 1 & 2 |
Moderate to severe plaque psoriasis |
PASI 90 achievement |
85-88% |
Nasopharyngitis, headache |
| NAVIGATE |
PsA patients previously on biologics |
ACR20 response |
78% |
Upper respiratory infections |
Market Analysis of Guselkumab
Market Penetration and Revenue
- Global psoriasis market (2023): Estimated $8.4 billion, with biologics comprising ~70% (~$5.9B).
- Guselkumab’s market share: Approximately 12%, with revenues reaching ~$800 million in 2022.
- Major markets: US (50%), EU (30%), Japan and AU (20%).
Competitive Landscape
| Key Competitors |
Mechanism of Action |
Approval Year |
Market Share (2022) |
Notes |
| Ustekinumab (Stelara) |
IL-12/23 inhibition |
2009 |
20% |
Longer market presence |
| Secukinumab (Cosentyx) |
IL-17A inhibition |
2015 |
15% |
Strong psoriasis efficacy |
| Risankizumab (Skyrizi) |
IL-23 inhibition |
2019 |
10% |
Similar target, newer entrant |
| Risankizumab use in PsA |
|
|
|
Growing, but guselkumab leads in some segments |
Growth Drivers
- Expanded indications: Crohn’s disease (Phase 3), atopic dermatitis (Phase 2).
- Improved dosing regimen: Q8W (every 8 weeks) compared to competitors.
- Increased patient compliance owing to favorable safety profile.
- Geographic expansion: Japan (2019), additional EU countries.
Market Limitations and Challenges
- High molecule cost (~$60,000/year).
- Competition from biosimilars and generics in other classes.
- Regulatory delays or concerns in emerging markets.
Regulatory Milestones (2022–2023)
| Country |
Approval Date |
Indication |
| US |
2017 |
Moderate to severe plaque psoriasis |
| EU |
2018 |
Psoriasis, psoriatic arthritis |
| Japan |
2020 |
Psoriasis, psoriatic arthritis |
| Canada |
2019 |
Psoriasis, psoriatic arthritis |
Market Projection (2023–2028)
Forecast Assumptions
- CAGR of 12% based on increased indication approvals and market penetration.
- Introduction of biosimilars expected post-2025, potentially impacting prices.
- Ongoing clinical trials expanding indications may add an additional revenue stream.
- Geographically, Asia-Pacific and Latin America expected to contribute 25% of growth.
Projected Revenue Table
| Year |
Global Guselkumab Revenue (USD Million) |
Growth Rate |
Market Share |
Key Drivers |
| 2023 |
850 |
— |
12% |
Existing approvals, stable market share |
| 2024 |
950 |
12% |
12% |
Expanded indications, new marketplaces |
| 2025 |
1,070 |
12.6% |
13% |
Biosimilar entry, price adjustments |
| 2026 |
1,200 |
12.1% |
14% |
Increased utilization, more indications |
| 2027 |
1,350 |
12.5% |
15% |
Regulatory approvals in additional indications |
| 2028 |
1,520 |
12.9% |
16% |
Broader market adoption, biosimilar competition begins |
Comparison with Other IL-23/IL-17 Blockers
| Attribute |
Guselkumab |
Risankizumab |
Tildrakizumab |
Ustekinumab |
| Approval Year |
2017 |
2019 |
2018 |
2009 |
| Dosing Frequency |
Q8W |
Q8W |
Q12W, Q4W (depending) |
Q12W (after induction) |
| Efficacy (PASI 90/100%) |
~85-88% / ~70% |
Similar (~85-90%) |
~70-75% |
~70% |
| Safety Profile |
Favorable |
Similar |
Slightly lower safety profile |
Well established |
| Market Share (2022) |
12% |
10% |
5% |
20% |
FAQs
1. What new indications are currently in clinical development for guselkumab?
Guselkumab is under investigation for Crohn’s disease (Phase 3), atopic dermatitis (Phase 2), and hidradenitis suppurativa (Phase 2). Positive trial results could further expand its market.
2. How does guselkumab’s efficacy compare to other biologics for psoriasis?
Based on Phase 3 trial data, guselkumab demonstrates high efficacy, with PASI 90 responses in over 85% of patients at Week 16, comparable to risankizumab and superior to ustekinumab.
3. What are the main safety concerns associated with guselkumab?
Adverse events are generally mild and include nasopharyngitis, headache, and upper respiratory infections. Serious adverse events are rare, with an excellent safety profile observed in long-term studies.
4. How will biosimilar entry impact guselkumab's market?
Biosimilars may reduce pricing and increase access but could also erode market share. Janssen is likely to maintain competitive differentiation through indication expansion and pharmacoeconomic strategies.
5. Which geographies are the primary growth markets for guselkumab?
The US and Europe remain dominant, but Asia-Pacific and Latin America are expanding rapidly, driven by increasing psoriasis prevalence and healthcare access improvements.
Key Takeaways
- Clinical Development: Guselkumab remains a leading IL-23 inhibitor with a robust pipeline and demonstrated efficacy in multiple immune-mediated diseases.
- Market Position: It holds approximately 12% of the global biologic psoriasis market, with revenues approaching $850 million annually.
- Growth Prospects: CAGR of 12% projected through 2028, driven by expanded indications, geographic expansion, and increasing patient access.
- Competitive Edge: Superior efficacy and safety profile relative to older biologics, with the potential to sustain market leadership amid biosimilar competition.
- Strategic Focus: Continued clinical trials for other indications and geographic expansion are critical for sustainable growth.
Sources
[1] ClinicalTrials.gov. (2023). Guselkumab Trials.
[2] Johnson & Johnson. Earnings Reports, 2022.
[3] Evaluate Pharma. (2023). Biologic Market Trends.
[4] EMA & FDA approvals. (2017–2023).
[5] MarketWatch. (2023). Biologic Drug Market Analysis.
